ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos53.14 M56.18 M63.67 M63.37 M63.76 M69.74 M260.54 MInvestigación y desarrollo21.14 M21.31 M23.92 M18.05 M17.01 M17.13 M76.11 MBeneficio operativo-36.04 M-34.64 M-41.56 M-30.12 M-29.93 M-32.9 M-134.51 MTotal de ingresos no operativos1.32 M3.17 M2.55 M1.85 M2.91 M2.65 M9.96 MGastos por intereses, netos de intereses capitalizados29 K24 K143 K————Ingresos no operativos, una vez deducidos los gastos por intereses3.59 M3.22 M2.66 M2.69 M2.63 M2.17 M10.16 MIngresos/gastos extraordinarios-2.3 M-69 K-251 K-836 K277 K471 K-339 KBeneficio antes de impuestos-34.75 M-31.5 M-39.15 M20.58 M-26.88 M-30.25 M-75.71 MParticipación en los beneficios———————Impuestos-96 K97 K175 K191 K256 K253 K875 KParticipación minoritaria———————Otros ingresos/gastos después de impuestos—20 K-831 K-1.15 M-240 K336 K-1.89 MBeneficio neto antes de actividades interrumpidas-34.66 M-31.59 M-39.33 M20.39 M-27.14 M-30.51 M-76.58 MOperaciones suspendidas———————Beneficio neto-34.66 M-31.59 M-39.33 M20.39 M-27.14 M-30.51 M-76.58 MAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas-34.66 M-31.59 M-39.33 M20.39 M-27.14 M-30.51 M-76.58 MBeneficio básico por acción-0.59-0.53-0.660.34-0.45-0.5-1.27Beneficio por acción diluido-0.59-0.53-0.660.33-0.44-0.5-1.27Número medio de acciones ordinarias58.02 M59.16 M59.65 M59.99 M59.81 M61.08 M240.53 MAcciones diluidas58.02 M59.16 M59.65 M61.16 M59.81 M61.08 M241.7 MEBITDA-29.39 M-28.26 M-35.16 M-24.05 M-23.93 M-26.71 M-109.85 MEBIT-36.04 M-34.64 M-41.56 M-30.12 M-29.93 M-32.9 M-134.51 MCosto de los ingresos46.48 M45.87 M46.77 M44.76 M48.17 M49.73 M189.42 MOtros costes de producción———————Amortización y depreciación (flujo de caja)6.66 M6.38 M6.4 M6.07 M6 M6.19 M24.67 M
Twist Bioscience Corporation
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes.